Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):352–359. doi: 10.1038/sj.bjc.6690362

Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts

E Jacobs 2, S A Watson 2, D Michaeli 3, I O Ellis 1, J F R Robertson 1
PMCID: PMC2362318  PMID: 10408837

Abstract

The human breast cancer cell line (MCF7) was established as xenografts in intact female nude mice. Xenografts did not require oestrogen supplementation for growth, although oestrogen supplementation caused more rapid tumour growth. GnRH Pharmaccine is an immunogen composed of gonadotrophin releasing hormone (GnRH) linked to diphtheria toxoid. Anti-GnRH antibodies purified from the serum of rabbits immunized with GnRH Pharmaccine, were used to passively immunize nude mice. In mice treated with anti-GnRH antibodies, xenograft growth was significantly inhibited relative to controls (median times of 71 and 29 days respectively taken for tumours to attain a predetermined cross-sectional area of 200 mm2, P < 0.001). The inhibition of tumour growth achieved by anti-GnRH antibodies was not significantly different from that produced by the anti-oestrogen, tamoxifen (59 days). Ovarian/uterine weights were reduced by 61% (P < 0.001) in anti-GnRH antibody-treated animals compared with controls. Histologically there was underdevelopment and atrophy of the reproductive organs. Serum levels of both oestrogen and luteinizing hormone were reduced by treatment with anti-GnRH antibodies (to 24.9% and 53% respectively of levels in controls, both P = 0.04). It is postulated that one of the mechanisms by which anti-GnRH antibody treatment inhibits tumour growth is indirectly, by reducing serum oestrogen levels. © 1999 Cancer Research Campaign

Keywords: breast cancer, xenograft, GnRH, immunotherapy

Full Text

The Full Text of this article is available as a PDF (552.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blamey R. W., Jonat W., Kaufmann M., Bianco A. R., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer. 1992;28A(4-5):810–814. doi: 10.1016/0959-8049(92)90120-q. [DOI] [PubMed] [Google Scholar]
  2. Cho H., Aronica S. M., Katzenellenbogen B. S. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology. 1994 Feb;134(2):658–664. doi: 10.1210/endo.134.2.7507831. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  4. Ferro V. A., Stimson W. H. Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer. Eur J Cancer. 1997 Aug;33(9):1468–1478. doi: 10.1016/s0959-8049(97)00126-3. [DOI] [PubMed] [Google Scholar]
  5. Gottardis M. M., Robinson S. P., Jordan V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem. 1988;30(1-6):311–314. doi: 10.1016/0022-4731(88)90113-6. [DOI] [PubMed] [Google Scholar]
  6. Goulding H., Pinder S., Cannon P., Pearson D., Nicholson R., Snead D., Bell J., Elston C. W., Robertson J. F., Blamey R. W. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995 Mar;26(3):291–294. doi: 10.1016/0046-8177(95)90060-8. [DOI] [PubMed] [Google Scholar]
  7. Jacobs E., Watson S. A., Hardcastle J. D., Robertson J. F. Oestrogen and progesterone receptors in gastrointestinal cancer cell lines. Eur J Cancer. 1996 Dec;32A(13):2348–2353. doi: 10.1016/s0959-8049(96)00363-2. [DOI] [PubMed] [Google Scholar]
  8. Kraus W. L., Katzenellenbogen B. S. Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology. 1993 Jun;132(6):2371–2379. doi: 10.1210/endo.132.6.8504742. [DOI] [PubMed] [Google Scholar]
  9. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  10. Osborne C. K., Hobbs K., Clark G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb;45(2):584–590. [PubMed] [Google Scholar]
  11. Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Williamson K., Robertson J. F., Ellis I. O., Elston C. W., Nicholson R. I., Blamey R. W. Effect of LHRH agonist, Zoladex, on ovarian histology. Br J Surg. 1988 Jun;75(6):595–596. doi: 10.1002/bjs.1800750634. [DOI] [PubMed] [Google Scholar]
  13. Yano T., Korkut E., Pinski J., Szepeshazi K., Milovanovic S., Groot K., Clarke R., Comaru-Schally A. M., Schally A. V. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat. 1992;21(1):35–45. doi: 10.1007/BF01811962. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES